ERRATA

Following is a list of errata and corrections to *USP–NF*. The page number indicates where the item is found and in which official or pending official publication of *USP–NF*. This list will be updated with the posting of errata reports on www.usp.org/USPNF/newOfficialText. This information will appear in its corrected form in a future annual edition of *USP–NF*. An erratum consists of content erroneously published that does not accurately reflect the intended official or effective requirements as approved by the Council of Experts. USP staff is available to respond to questions regarding the accuracy of a particular requirement by calling 1-800-822-USPC.

Page Number	Title	Section	Description
USP34–NF29			
1153	*Ginkgo Capsules*	PERFORMANCE TESTS *Disintegration and Dissolution* ⟨2040⟩	Line 5 of *Analysis*: Change "Result = 5000 × (C/3) × G" to: Result = 5000C/3G
1154	*Ginkgo Tablets*	PERFORMANCE TESTS *Disintegration and Dissolution of Dietary Supplements* ⟨2040⟩	Line 5 of *Analysis*: Change "Result = 5000 × (C/3) × G" to: Result = 5000C/3G
1164	*Glucosamine and Chondroitin Sulfate Sodium Tablets*	*Content of glucosamine*	Line 12 of *Procedure*: Change "(179.17/215.63)(100C)(r_U/r_S)" to: (179.17/215.63)(25C)(r_U/r_S)
1479	*Carmellose*	IMPURITIES *Chlorides*	Line 9 of *Sample solution*: Change "Take 25 mL of this solution, add 6 mL of nitric acid, and dilute with water to make 50 mL." to: Take 25 mL of this solution, add 6 mL of nitric acid, diluted, and dilute with water to make 50 mL.
			Line 1 of *Control solution*: Change "0.40 mL of 0.01 N hydrochloric acid VS and 6 mL of dilute nitric acid. Add water to make 50 mL." to: 0.40 mL of 0.01 N hydrochloric acid VS and 6 mL of nitric acid, diluted. Add water to make 50 mL.
1514	*Diethylene Glycol Monoethyl Ether*	*USP Reference standards* ⟨11⟩	Line 2: Change "USP Diethylene Glycol RS USP Monoethyl Ether RS" to: USP Diethylene Glycol Monoethyl Ether RS
1522	*Ethyl Acrylate and Methyl Methacrylate Copolymer Dispersion*	IMPURITIES *Organic Impurities, Procedure: Limit of Monomers*	Line 13 of *Analysis*: Change "C_U = concentration of each monomer in the *Sample stock solution* (mg/mL)" to: C_U = concentration of Ethyl Acrylate and Methyl Methacrylate Copolymer Dispersion in the *Sample stock solution* (mg/mL)
2364	*Clarithromycin Extended-Release Tablets*	*Dissolution* ⟨711⟩, *Test 2*	Line 7 of the second paragraph of *Procedure*: Change "*n* is the number of time points [NOTE—The summation of the amount of clarithromycin removed at previous sampling time points is applicable only where n>1."] to: $\sum_{i=1}^{n-1} C_i$ *n* is the number of time points; $\sum_{i=1}^{n-1} C_i$ is the summation of the concentration of the *Test solution* from the first to the (*n*–1)th time point [NOTE—The summation of the amount of clarithromycin removed at previous sampling time points is applicable only where n>1.]

2364	*Clarithromycin Extended-Release Tablets (continued)*	*Dissolution* ⟨711⟩, *Test 3*	Line 7 of the second paragraph of *Procedure*: Change "*n* is the time point (at 2 hours, *n* = 2), summation of the concentration of the *Test solution* from the first to the (*n*–1)th time point (only applicable for $n \geq 2$)" to: *n* is the time point (at 2 hours, *n* = 2); $\sum_{i=1}^{n-1} C_i$ is the summation of the concentration of the *Test solution* from the first to the (*n*–1)th time point (only applicable for $n \geq 2$)
2412	*Clotrimazole Topical Solution*	*Assay*	Line 1: Change "*Dibasic potassium phosphate solution* and *Mobile phase*—Prepare as directed in the *Assay* under *Clotrimazole*." to: *Buffer*—Prepare as directed in the *Assay* under *Clotrimazole*. *Mobile phase*—Methanol and *Buffer* (3:1)
2412	*Clotrimazole Vaginal Inserts*	*Assay*	Line 1: Change "*Dibasic potassium phosphate solution* and *Mobile phase*—Prepare as directed in the *Assay* under *Clotrimazole*." to: *Buffer*—Prepare as directed in the *Assay* under *Clotrimazole*. *Mobile phase*—Methanol and *Buffer* (3:1)
2479	*Deferoxamine Mesylate for Injection*	*Identification*	Line 1: Change "It responds to the *Identification* test under *Deferoxamine Mesylate*." to: Dissolve 5 mg in 5 mL of water, add 2 mL of tribasic sodium phosphate solution (1 in 200), mix, then add 10 drops of β-naphthoquinone-4-sodium sulfonate solution (1 in 40): a blackish brown color is produced.
		Assay	Line 1: Change "*Ferric chloride solution* and *Standard preparation*—Prepare as directed in the *Assay* under *Deferoxamine Mesylate*." and "*Procedure*—Proceed as directed in the *Assay* under *Deferoxamine Mesylate*." to: *Ferric chloride solution*—Dissolve 6.7 g of ferric chloride in dilute hydrochloric acid (1 in 100) in a 100-mL volumetric flask. Add dilute hydrochloric acid (1 in 100) to volume, mix, and filter. *Standard preparation*— Dissolve a suitable quantity of USP Deferoxamine Mesylate RS, accurately weighed, in water to obtain a solution having a known concentration of about 1000 µg per mL. and *Procedure*—Pipet 2 mL each of the *Standard preparation*, *Assay preparation*, and water to provide a blank, into separate 25-mL volumetric flasks. To each flask add 3 mL of *Ferric chloride solution*, dilute with water to volume, and mix. Concomitantly determine the absorbances of the solutions from the *Standard preparation* and the *Assay preparation* against the blank, in 1-cm cells, at the wavelength of maximum absorbance at about 485 nm, with a suitable spectrophotometer.
2573	*Dihydroergotamine Mesylate*	*Assay*	*Chromatographic system*, line 5, column 1 of the *Table*: Change "20–25" to: 20–24
2688	*Enflurane*	*Limit of fluoride ions*	Line 1 of *Procedure*: Change "*Titrimetry* ⟨541⟩" to: *pH* ⟨791⟩
3096	*Hypromellose*	SPECIFIC TESTS *Viscosity* ⟨911⟩, *For hypermellose samples having a viscosity of less than 600 mPa·s*	Line 13 of *Sample solution*: Change "Centrifuge the solution to expel any entrapped air." to: Centrifuge the solution, if necessary, to expel any entrapped air.

4219	*Sertraline Tablets*	IMPURITIES *Organic Impurities*	Line 2 of *Resolution*: Change "sertraline hydrochloride" to: sertraline
4364	*Terbinafine Tablets*	IMPURITIES *Organic Impurities, Procedure 2: Limit of Terbinafine Dimer*	Line 1 of *Solution B*: Change "1 mL of triethyl amine" to: 1 mL/L of triethyl amine
4587	*Vincristine Sulfate for Injection*	IMPURITIES *Organic Impurities*	Delete: "*System suitability solution*, *Standard solution*, and *System suitability*: Proceed as directed in the *Assay*."
Revision Bulletin (Official July 1, 2011)			
Online	*Vincristine Sulfate*	IMPURITIES *Organic Impurities*	Delete: "*Standard solution*, *System suitability solution*, and *System suitability*: Proceed as directed in the *Assay*."
Online	*Vincristine Sulfate Injection*	ASSAY *Procedure*	Line 1 of *Sample solution*: Change "1.2 mg/mL" to: 1.0 mg/mL
Online	*Zolpidem Tartrate Extended-Release Tablets*	PERFORMANCE TESTS *Dissolution* ⟨711⟩, *Test 1*	Line 3, column 2 of *Table 1*: Change "70%–90%" to: 70%–85%
Revision Bulletin (Official August 1, 2011)			
Online	*Levofloxacin*	IMPURITIES *Organic Impurities, Procedure 2*	Line 4, after the *Note*: Add "*Buffer:* Dissolve 3.08 g/L of ammonium acetate and 8.43 g/L of sodium perchlorate monohydrate in water. Adjust with phosphoric acid to a pH of 2.2."
First Supplement to USP34–NF29			
4865	*Description and Solubility*	*Losartan Potassium*	Line 1: Change "White to off-white powder. Freely soluble in water; soluble in isopropyl alcohol; slightly soluble in acetonitrile." to: White to off-white powder. Freely soluble in water; sparingly soluble in isopropyl alcohol; slightly soluble in acetonitrile.
4920	*Bupropion Hydrochloride Extended-Release Tablets*	ASSAY *Procedure*	Line 1 of *System suitability solution A*: Change "0.0018 mg/mL of USP Bupropion Related Compound C RS and 0.018 mg/mL of USP Bupropion Related Compound F RS from *System suitability stock solution A* and *Diluent*" to: 0.0018 mg/mL of USP Bupropion Hydrochloride Related Compound C RS and 0.018 mg/mL of USP Bupropion Hydrochloride Related Compound F RS from *System suitability stock solution A* and *Diluent*
4957	*Escitalopram Oxalate*	IMPURITIES *Organic Impurities*	Line 8 of *Analysis*: Change "r_S = peak response of escitalopram from the *Sample solution*" to: r_S = peak response of escitalopram from the *Standard solution*
5054	*Valacyclovir Tablets*	PERFORMANCE TESTS *Dissolution* ⟨711⟩	Line 4 of *Analysis*: Change "Result = $(r_U/r_S) \times (C_S) \times (M_{r1}/M_{r2}) \times (1/L) \times 100 \times 900$" to: Result = $(r_U/r_S) \times (C_S) \times (M_{r1}/M_{r2}) \times (1/L) \times D \times 100 \times 900$
			Line 9 of *Analysis*: Add "D = dilution factor of the *Sample solution*"
		PERFORMANCE TESTS *Uniformity of Dosage Units* ⟨905⟩	Line 2, before the *Note*: Add "Procedure for content uniformity"
5055	*Vincristine Sulfate Injection*	IMPURITIES *Organic Impurities*	Delete "*System suitability solution*, *Standard solution*, and *System suitability*: Proceed as directed in the *Assay*."
Second Supplement to USP34–NF29			
5378	*Alclometasone Dipropionate*	ASSAY *Procedure*	Line 1 of *Resolution*: Change "NLT 3.0 between the analyte and the *Internal standard solution* peaks" to: NLT 3.0 between the analyte and the internal standard peaks

5383	*Amoxicillin and Clavulanate Potassium Tablets*	ASSAY *Procedure*	Line 1 of *Sample solution*: Change "Dilute a suitable volume of the *Sample stock solution* filtrate with water to obtain a solution containing 0.5 mg/mL of amoxicillin." to: Dilute a suitable volume of the *Sample stock solution* with water to obtain a solution containing 0.5 mg/mL of amoxicillin.
5435	*Leuprolide Acetate*	IMPURITIES *Chromatographic Purity*	Line 6 of *Analysis*: Change "Result = $(r_U/r_S) \times (W_S/W_U) \times P \times$ ●M●(IRA 1-Feb-2011) $\times$ 0.01" to: Result = $(r_U/r_S) \times (C_S/C_U) \times P \times$ ●M●(IRA 1-Feb-2011) Line 11 of *Analysis*: Change "r_S = peak response of leuprolide from the *Standard stock solution* W_S = weight of USP Leuprolide Acetate RS in the *Standard stock solution* (mg) W_U = weight of Leuprolide Acetate in the *Sample solution* (mg)" to: r_S = peak response of leuprolide from the *Standard solution* C_S = concentration of USP Leuprolide Acetate RS in the *Standard solution* (mg/mL) C_U = concentration of Leuprolide Acetate in the *Sample solution* (mg/mL)
5450	*Norethindrone Acetate and Ethinyl Estradiol Tablets*	PERFORMANCE TESTS *Dissolution* ⟨711⟩	Line 3 of *0.025 M acetate buffer solution*: Change "3.5 mL" to: 3.5 L